ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Liposomal Bupivacaine

Also written as “EXPAREL”, “bupivacaine liposome injectable suspension” and “Exparel”.

Its studies are mostly in Pain, Postoperative · Pain · Bunion · Intestinal Obstruction · Hallux Valgus, led by 4 companies.

Drug pageLiposomal Bupivacaine: every studyAll 299 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Oct 23, 201139 company-led studies, 1 open or runningNext primary completion: Jan 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pacira BioSciencesits history only361 open or runningphase 4since Oct 23, 2011Oct 23, 2011Jan 2027phase 1 · NCT06271265
Heron Therapeuticsits history only10 open or runningphase 4since Sep 23, 2019Sep 23, 2019none ahead
Jiangsu HengRui Medicineits history only10 open or runningphase 1since Dec 1, 2025Dec 1, 2025none ahead
Nuance Pharma (shanghai)10 open or runningphase 1since Nov 5, 2019Nov 5, 2019none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Nuance Pharma (shanghai) only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 5, 2019First study: phase 1 study in Healthy SubjectsFirst studyNCT04158102 · 20 enrolled · China

TargetBeta

SCN4A →read by rule
“Sodium channel protein type IV alpha subunit blocker; Sodium channel protein type IV alpha subunit blocker”ChEMBL 37, by rule

Other programs on SCN4A

ProgramCompanyFurthest phaseStudies
LidocaineruleKeenova Therapeuticsphase 463
LamotrigineruleGlaxoSmithKlinephase 461
RanolazineruleGilead Sciencesphase 426
Carbamazepinerulegrin-therapeutics-incphase 421
DronedaroneruleSanofiphase 418
chloroprocainerulesintetica-saphase 48
RiluzoleruleSanofiphase 46
PrilocaineruleHaisco Pharmaceutical Groupphase 42
CarticaineruleLaboratoires Theaphase 41
Ropivacainerulepainreform-ltdphase 317
QuinidineruleOtsukaphase 317
PhenytoinruleViatrisphase 310

Studies

The one study Nuance Pharma (shanghai) leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04158102Healthy Subjects · China1CompletedDec 17, 201920

How it is read

Names in the registry

  • “EXPAREL”, 15 entries
  • “bupivacaine liposome injectable suspension”, 4 entries
  • “Exparel”, 3 entries
  • “Exparel Injectable Product”, 2 entries
  • “EXPAREL 266 mg”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.